Brief: European Commission Grants Orphan Medicinal Product Designation For Navenibart, Astria Therapeutics’ Investigational Therapy For The Treatment Of Hereditary Angioedema
16/10/2024 13:01
Oct 16 (Reuters) - Astria Therapeutics Inc ATXS.O :
* EUROPEAN COMMISSION GRANTS ORPHAN MEDICINAL PRODUCT
DESIGNATION
FOR NAVENIBART, ASTRIA THERAPEUTICS’ INVESTIGATIONAL THERAPY FOR
THE TREATMENT OF HEREDITARY ANGIOEDEMA
Source text for Eikon: ID:nBw5Q3kZRa
Further company coverage: ATXS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Astria Therapeutics
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:28 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:28 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 07:59 PM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM